SCHEMBL21801498

SCHEMBL21801498

Cc1c(-c2nnc(SCCc3ccccc3)o2)[nH]c2ccc(Cl)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 1/20 0.46
▸ QPCT Q16769 2/20 0.46
▸ MAPT P10636 5/20 0.45
▸ MEN1 O00255 4/20 0.45
▸ KMT2A Q03164 4/20 0.45
▸ LMNA P02545 3/20 0.45
▸ PTGS2 P35354 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.42
▸ CNR1 P21554 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ TP53 P04637 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ ESR1 P03372 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21801479 0.95 QPCT (0.48) GSK3BQPCTMAPTMEN1KMT2A
SCHEMBL21801525 0.91 MAPT (0.53) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL21801488 0.88 CNR1 (0.46) GSK3BQPCTMAPTMEN1KMT2A
SCHEMBL21801673 0.83 QPCT (0.47) GSK3BQPCTMAPTMEN1KMT2A
SCHEMBL21801696 0.82 MAPT (0.50) QPCTMAPTMEN1KMT2ALMNA
SCHEMBL21801555 0.81 PTGS2 (0.49) PTGS2CNR1NPC1RAB9AEGFR
SCHEMBL21801461 0.80 MAPK1 (0.50) GSK3BQPCTMAPTMEN1KMT2A
SCHEMBL24750230 0.80 PTGS2 (0.46) MAPTLMNAPTGS2CNR1TP53
SCHEMBL21801678 0.79 MAPT (0.54) GSK3BQPCTMAPTMEN1KMT2A
SCHEMBL21801466 0.78 MAPT (0.51) MAPTMEN1KMT2ALMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220257569-A1 INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2022-08-18 — — US disclosed
WO-2020051707-A1 INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2020-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220257569-A1 INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE CNR2, GPR119, CNR1 GSK3B 116/4885QPCT 2631/4885MAPT 2269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback